FDAnews
www.fdanews.com/articles/205201-pfizer-pledges-warranty-for-nsclc-drug-should-it-fail-to-provide-benefit

Pfizer Pledges Warranty for NSCLC Drug Should It Fail to Provide Benefit

November 5, 2021

Pfizer has quietly launched what it’s calling the Pfizer Pledge, a pilot program that attaches an insurance-backed warranty to the performance of the company’s 10-year-old lung cancer drug Xalkori, promising money back.

The pledge: If Xalkori (crizotinib) doesn’t work in the first three months of treatment in U. S. patients with metastatic nonsmall-cell lung cancer (NSCLC), Pfizer will refund the cost of the drug to whomever paid for it — whether a cash-paying patient, an insurance company or Medicare Part D.

Specifically, said Pfizer in a statement to FDAnews, the program is available to patients prescribed Xalkori for metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. It’s also available to pediatric patients who are one year old or older and young adults with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) that is ALK-positive.

A 30-day supply of Xalkori is $19,144, according to Pfizer’s webpage on the program. Each patient in the program can get a maximum of $57,432 back if they take the drug for three months and can show that they experienced no benefit.

View today's stories